Meningococcal Conjugate Vaccines (MCV4) for Persons Aged 11 Years and Older

**Indications for Use and Schedule**

- **Routinely administer:**
  - One dose at aged 11-12 years; 2nd dose at age 16 years
  - Preferred for ages 56 years & older who previously received MCV4 or who are recommended to receive multiple doses of meningococcal vaccine

- **Adolescent catch-up schedule:**
  - If 1st dose given at aged 13 through 15 years, give a 2nd dose at aged 16 through 18 years
  - If 1st dose given at age 16 years or older, a 2nd dose is not recommended

- **Minimum Interval**
  - 8 weeks between 2 doses for all ages

**Contraindications**

- An anaphylactic (severe allergic) reaction to a prior dose or a component of MCV4 vaccine

**Precautions**

- Moderate to severe acute illness with or without fever

**Further Points**

- Both MCV4 vaccines protect against serotype A, C, W, Y; Serotype B is not in either vaccine. Meningococcal B (MenB) vaccines protect against B
- Persons indicated for a 2-dose primary series who previously received only 1 dose of MCV4, should get a 2nd dose of MCV4 as soon as feasible; forecast the booster dose (if applicable) from the date of the 2nd primary series dose
- Persons aged 56 years or older who have never received a meningococcal vaccine and anticipate needing only on dose, MPSV4 (meningococcal polysaccharide vaccine) is preferred
- Persons who inadvertently receive MPSV4 should be revaccinated with MCV4 using a minimum interval of 8 weeks
- Meningococcal Vaccine Information Statement (VIS), can be found at http://www.immunize.org/vis/

1. If a MCV4 dose is given at age 10 years, will count as the age 11-12 years/1st dose of the adolescent series; give next dose at age 16 years
2. Recommended interval is 3-5 years but if unlikely to return at later date, give 2nd dose at age 16 years and at least 8 weeks after last dose
3. PCV13 is Pneumococcal Conjugate Vaccine; ensure at least one dose of PCV13 (Prevnar13®) is given to all persons with asplenia
4. For persons aged 2 years or older with asplenia, give the PCV13 dose 1st and wait 4 weeks before giving Menactra (MCV4-D). Menveo (MCV4-CRM) can be given at the same time or at any interval before/after PCV13.

**Resources:** “Prevention and Control of Meningococcal Disease, Recommendations of the ACIP”, March 22, 2013, located at www.cdc.gov/vaccines/recs.

Adapted from the Michigan Department of Community Health  December 2015